Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | EVP, Head of R&D | July 23, 2018 | July 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date July 23, 2018 · Filed July 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.54 · Expires 2025-07-23 | Direct | 75,000 |
Reported balance
After 2018-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-23 · Grant · Acquired 75,000 · Balance 75,000 F1: This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2018 Filed Jul 25, 2018 20:49 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-18-043906 · doc4.xml · derivative · entry 1 Seidel Ronald D. III · CIK 0001724872 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2025-07-23 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.